[1]

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6): 394–424.

doi: 10.3322/caac.21492
[2]

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 1990 2018;49(6):1374–403.

[3]

Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014;20(38):13842–62.

doi: 10.3748/wjg.v20.i38.13842
[4]

Saumoy M, Schneider Y, Shen N, Kahaleh M, Sharaiha RZ, Shah SC. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology. 2018;155(3):648–60.

doi: 10.1053/j.gastro.2018.05.026
[5]

de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134(4):945–52.

doi: 10.1053/j.gastro.2008.01.071
[6]

Song H, Ekheden IG, Zheng Z, Ericsson J, Nyrén O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015;351:h3867.

[7]

Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74–94.

doi: 10.1055/s-0031-1291491
[8]

Chapelle N, Bouvier AM, Manfredi S, Drouillard A, Lepage C, Faivre J, et al. Early gastric cancer: trends in incidence, management, and survival in a well-defined French population. Ann Surg Oncol. 2016;23(11):3677–83.

doi: 10.1245/s10434-016-5279-z
[9]

Vance RB, Kubiliun N, Dunbar KB. How do we manage gastric intestinal metaplasia? A survey of clinical practice trends for gastrointestinal endoscopists in the United States. Dig Dis Sci. 2016;61(7):1870–8.

doi: 10.1007/s10620-016-4107-4
[10]

Li D, Bautista MC, Jiang SF, Daryani P, Brackett M, Armstrong MA, et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol. 2016;111(8):1104–13.

doi: 10.1038/ajg.2016.188
[11]

Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.

doi: 10.1136/gutjnl-2016-312288
[12]

Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10): 1161–81.

doi: 10.1097/00000478-199610000-00001
[13]

Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut. 1999;45(5):784–90.

doi: 10.1136/gut.45.5.784
[14]

Karter AJ, Parker MM, Moffet HH, Ahmed AT, Ferrara A, Liu JY, et al. Missed appointments and poor glycemic control: an opportunity to identify high-risk diabetic patients. Med Care. 2004;42(2):110–5.

doi: 10.1097/01.mlr.0000109023.64650.73
[15]

Nelson EA, Maruish ME, Axler JL. Effects of discharge planning and compliance with outpatient appointments on readmission rates. Psychiatr Serv. 2000;51(7):885–9.

doi: 10.1176/appi.ps.51.7.885
[16]

Jeppesen MH, Ainsworth MA. Telephone reminders reduced the non-attendance rate in a gastroenterology outpatient clinic. Dan Med J. 2015;62(6):

[17]

Guy R, Hocking J, Wand H, Stott S, Ali H, Kaldor J. How effective are short message service reminders at increasing clinic attendance? A meta-analysis and systematic review. Health Serv Res. 2012;47(2):614–32.

doi: 10.1111/j.1475-6773.2011.01342.x
[18]

Car J, Gurol-Urganci I, de Jongh T, Vodopivec-Jamsek V, Atun R. Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database Syst Rev. 2013;(7):CD007458.

[19]

Robotham D, Satkunanathan S, Reynolds J, Stahl D, Wykes T. Using digital notifications to improve attendance in clinic: systematic review and meta-analysis. BMJ Open. 2016;6(10):e012116.

doi: 10.1136/bmjopen-2016-012116
[20]

Chen ZW, Fang LZ, Chen LY, Dai HL. Comparison of an SMS text messaging and phone reminder to improve attendance at a health promotion center: a randomized controlled trial. J Zhejiang Univ Sci B. 2008;9(1):34–8.

doi: 10.1631/jzus.B071464
[21]

Childers RE, Laird A, Newman L, Keyashian K. The role of a nurse telephone call to prevent no-shows in endoscopy. Gastrointest Endosc. 2016;84(6):1010–e1.

doi: 10.1016/j.gie.2016.05.052
[22]

Agarin T, Okorafor E, Kailasam V, Agarin A, Philias W, Garcia D, et al. Comparing kept appointment rates when calls are made by physicians versus behavior health technicians in Inner City Hospital: literature review and cost considerations. Community Ment Health J. 2015;51(3):300–4.

doi: 10.1007/s10597-014-9812-x
[23]

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet Lond Engl. 2018;391:1023–75.

doi: 10.1016/S0140-6736(17)33326-3
[24]

Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS Ⅱ): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4): 365–88.

doi: 10.1055/a-0859-1883
[25]

den Hollander WJ, Holster IL, den Hoed CM, Capelle LG, Tang TJ, Anten MP, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut. 2018;68(4):585–93.

[26]

den Hoed CM, Holster IL, Capelle LG, de Vries AC, den Hartog B, Ter Borg F, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy. 2013;45(4):249–56.

doi: 10.1055/s-0032-1326379